Ratings Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:51 2024-12-09 am EST			5-day change	1st Jan Change
257.20 ^CHF	+0.08%		+0.67%	+5.19%

Dec. 09	Swiss Stocks Begin Week in Red Ahead of Key Monetary Policy Decisions	MT
Dec. 09	ROCHE HOLDINGS AG : Berenberg remains Neutral	ZD

Summary: Roche Holding AG

According to Refinitiv, the company's ESG score for its industry is good.

Highlights: Roche Holding AG

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.

Weaknesses: Roche Holding AG

The company's enterprise value to sales, at 3.63 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings Chart: Roche Holding AG

Source: Surperformance

ESG chart: Roche Holding AG

Source: Refinitiv

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Fundamentals	Composite Valuation	Composite Momentum	Capi. ($)
	ROCHE HOLDING AG				235B
	ELI LILLY AND COMPANY				744B
	NOVO NORDISK A/S				493B
	JOHNSON & JOHNSON				359B
	ABBVIE INC.				311B
	MERCK & CO., INC.				261B
	ASTRAZENECA PLC				211B
	NOVARTIS AG				205B
	AMGEN INC.				147B
	PFIZER, INC.				146B
	Average				311.16B
	Weighted average by Cap.

See all sector ratings

Investor Rating

Trading Rating

ESG Refinitiv

A+

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes